MA35016B1 - Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt - Google Patents

Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt

Info

Publication number
MA35016B1
MA35016B1 MA36290A MA36290A MA35016B1 MA 35016 B1 MA35016 B1 MA 35016B1 MA 36290 A MA36290 A MA 36290A MA 36290 A MA36290 A MA 36290A MA 35016 B1 MA35016 B1 MA 35016B1
Authority
MA
Morocco
Prior art keywords
imidazopyridazines
akt inhibitors
kinase akt
kinase
inhibitors
Prior art date
Application number
MA36290A
Other languages
English (en)
Inventor
Lars Bärfacker
William Johnston Scott
Andrea Hägebarth
Stuart Ince
Hartmut Rehwinkel
Oliver Politz
Roland Neuhaus
Hans Briem
Ulf Bömer
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Publication of MA35016B1 publication Critical patent/MA35016B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des imidazopyridazines de la formule (I) et un procédé pour leur fabrication et leur utilisation.
MA36290A 2011-04-07 2012-04-05 Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt MA35016B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472732P 2011-04-07 2011-04-07
PCT/EP2012/056300 WO2012136776A1 (fr) 2011-04-07 2012-04-05 Imidazopyridazines en tant qu'inhibiteurs de la kinase akt

Publications (1)

Publication Number Publication Date
MA35016B1 true MA35016B1 (fr) 2014-04-03

Family

ID=45953129

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36290A MA35016B1 (fr) 2011-04-07 2012-04-05 Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt

Country Status (42)

Country Link
US (2) US9206185B2 (fr)
EP (1) EP2694510B1 (fr)
JP (1) JP5906303B2 (fr)
KR (1) KR20140022057A (fr)
CN (1) CN103596957B (fr)
AP (1) AP3597A (fr)
AR (1) AR087148A1 (fr)
AU (1) AU2012238589B2 (fr)
BR (1) BR112013025777A2 (fr)
CA (1) CA2832374A1 (fr)
CL (1) CL2013002878A1 (fr)
CO (1) CO6862145A2 (fr)
CR (1) CR20130515A (fr)
CU (1) CU24263B1 (fr)
CY (1) CY1117163T1 (fr)
DK (1) DK2694510T3 (fr)
DO (1) DOP2013000226A (fr)
EA (1) EA024890B1 (fr)
EC (1) ECSP13013008A (fr)
ES (1) ES2558780T3 (fr)
GT (1) GT201300238A (fr)
HR (1) HRP20160011T1 (fr)
HU (1) HUE026323T2 (fr)
IL (1) IL228567A0 (fr)
JO (1) JO3068B1 (fr)
MA (1) MA35016B1 (fr)
ME (1) ME02316B (fr)
MX (1) MX336865B (fr)
NI (1) NI201300105A (fr)
PE (1) PE20141380A1 (fr)
PL (1) PL2694510T3 (fr)
PT (1) PT2694510E (fr)
RS (1) RS54480B1 (fr)
SG (1) SG193631A1 (fr)
SI (1) SI2694510T1 (fr)
SM (1) SMT201600001B (fr)
TN (1) TN2013000400A1 (fr)
TW (1) TWI535719B (fr)
UA (1) UA111739C2 (fr)
UY (1) UY34006A (fr)
WO (1) WO2012136776A1 (fr)
ZA (1) ZA201307223B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3289876T (pt) 2008-06-16 2022-10-28 Univ Tennessee Res Found Compostos para o tratamento do câncer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
RU2581367C2 (ru) 2010-03-01 2016-04-20 Джи Ти Икс, ИНК. Соединения для лечения рака
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
ME02316B (me) * 2011-04-07 2016-06-20 Bayer Ip Gmbh Imidazopiridazini kao inhibitori akt kinaze
EP2802588B1 (fr) * 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Pyrazolopyrimidines substituées comme inhibiteurs de kinase akt
JP6088542B2 (ja) * 2012-01-10 2017-03-01 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ａｋｔキナーゼ阻害剤としての置換イミダゾピラジン類
EA028246B1 (ru) * 2012-11-30 2017-10-31 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Фармацевтическая композиция
CA2904338C (fr) 2013-03-05 2022-07-05 University Of Tennessee Research Foundation Utilisation de derives de l'imidazole conjointement a un inhibiteur brafou a un inhibiteur mek dans le traitement du cancer
WO2014158467A1 (fr) * 2013-03-12 2014-10-02 Glaxosmithkline Llc Combinaison
JP2016517434A (ja) * 2013-03-14 2016-06-16 エピザイム，インコーポレイティド 癌を処置するための併用療法
EP3092242A1 (fr) * 2014-01-09 2016-11-16 Bayer Pharma Aktiengesellschaft Imidazopyridazines amido-substituées utiles dans le traitement des troubles hyperprolifératifs et/ou de l'angiogenèse
MA46888A (fr) * 2016-11-28 2021-06-02 Bristol Myers Squibb Co Inhibiteurs de gsk-3
EP3453706A1 (fr) 2017-09-08 2019-03-13 Basf Se Composés pesticides de l'imizazole

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2393724A1 (fr) 1999-12-23 2001-06-28 Nitromed, Inc. Inhibiteurs de cyclooxygenase-2 nitroses et nitrosyles, compositions et procedes d'utilisation
WO2001074815A2 (fr) 2000-03-31 2001-10-11 Ortho Mcneil Pharmaceutical, Inc. Imidazopyridines phenyle-substituees
DK1277754T3 (da) 2000-04-27 2005-11-14 Astellas Pharma Inc Imidazopyridinderivater
CA2518318A1 (fr) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Inhibiteurs d'histone deacetylase
CN1809354A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
CA2534292A1 (fr) 2003-07-30 2005-02-17 Laboratorios S.A.L.V.A.T., S.A. Imidazopyrimidines substituees pour la prevention et le traitement du cancer
CA2561311A1 (fr) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibiteurs de l'activite d'akt
CN101217958A (zh) 2004-08-23 2008-07-09 默克公司 Akt活性抑制剂
EP1786780A1 (fr) 2004-08-24 2007-05-23 Basf Aktiengesellschaft Sulfites d'imidazolium-methyle utilises comme composes de depart ausgangsverbindungen pour la production de liquides ioniques
US7910561B2 (en) 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1902056A2 (fr) 2005-05-20 2008-03-26 Array Biopharma, Inc. Composes inhibiteurs raf et procedes d'utilisation de ceux-ci
CA2610888C (fr) 2005-06-10 2011-02-08 Merck & Co., Inc. Inhibiteurs de l'activite akt
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
AU2008262038A1 (en) * 2007-06-08 2008-12-18 AbbVie Deutschland GmbH & Co. KG 5-heteroaryl substituted indazoles as kinase inhibitors
JP5327652B2 (ja) * 2007-08-14 2013-10-30 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 癌処理のための融合されたイミダゾール
RS52559B (en) 2007-08-14 2013-04-30 Bayer Intellectual Property Gmbh FUSIONED BICYCLIC PYRIMIDINES
WO2009086130A1 (fr) 2007-12-21 2009-07-09 Wyeth Composés d'imidazo-[1,2-b]-pyridazine comme modulateurs des récepteurs x du foie
CA2726358A1 (fr) 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibiteurs de l'activite akt
US8207169B2 (en) 2008-06-03 2012-06-26 Msd K.K. Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
CA2750051A1 (fr) 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibiteurs de l'activite d'akt
CN102317291B (zh) * 2009-02-13 2015-02-11 拜耳知识产权有限责任公司 稠合嘧啶
WO2010104933A1 (fr) 2009-03-11 2010-09-16 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
WO2010114780A1 (fr) * 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
AR076936A1 (es) 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
WO2011033265A1 (fr) * 2009-09-18 2011-03-24 Almac Discovery Limited Composés pharmaceutiques
CN103097384B (zh) 2010-07-12 2017-02-15 拜耳知识产权有限责任公司 取代的咪唑并[1,2‑a]嘧啶和吡啶
JP5926727B2 (ja) * 2010-07-28 2016-05-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾ［１，２−ｂ］ピリダジン
ME02316B (me) * 2011-04-07 2016-06-20 Bayer Ip Gmbh Imidazopiridazini kao inhibitori akt kinaze

Also Published As

Publication number Publication date
UY34006A (es) 2012-10-31
RS54480B1 (en) 2016-06-30
EA024890B1 (ru) 2016-10-31
SMT201600001B (it) 2016-02-25
MX2013011699A (es) 2014-01-31
HUE026323T2 (en) 2016-05-30
JP5906303B2 (ja) 2016-04-20
US20150368250A1 (en) 2015-12-24
ME02316B (me) 2016-06-20
BR112013025777A2 (pt) 2016-12-20
US9604989B2 (en) 2017-03-28
WO2012136776A1 (fr) 2012-10-11
NZ616270A (en) 2015-09-25
CU20130135A7 (es) 2014-02-28
KR20140022057A (ko) 2014-02-21
IL228567A0 (en) 2013-12-31
US20140113901A1 (en) 2014-04-24
CN103596957A (zh) 2014-02-19
JO3068B1 (ar) 2017-03-15
AP3597A (en) 2016-02-19
MX336865B (es) 2016-02-04
CL2013002878A1 (es) 2014-05-02
SI2694510T1 (sl) 2016-02-29
CY1117163T1 (el) 2017-04-05
DOP2013000226A (es) 2013-11-15
TN2013000400A1 (en) 2015-03-30
TW201245204A (en) 2012-11-16
CN103596957B (zh) 2016-12-07
EP2694510A1 (fr) 2014-02-12
PT2694510E (pt) 2016-02-08
ECSP13013008A (es) 2013-12-31
PL2694510T3 (pl) 2016-03-31
EA201301130A1 (ru) 2014-07-30
ES2558780T3 (es) 2016-02-08
CR20130515A (es) 2013-12-04
PE20141380A1 (es) 2014-10-18
AU2012238589B2 (en) 2017-02-16
HRP20160011T1 (hr) 2016-02-12
UA111739C2 (uk) 2016-06-10
CU24263B1 (es) 2017-07-04
US9206185B2 (en) 2015-12-08
NI201300105A (es) 2014-07-14
TWI535719B (zh) 2016-06-01
GT201300238A (es) 2015-04-06
SG193631A1 (en) 2013-11-29
JP2014510127A (ja) 2014-04-24
CA2832374A1 (fr) 2012-10-11
AR087148A1 (es) 2014-02-26
ZA201307223B (en) 2014-12-23
CO6862145A2 (es) 2014-02-10
AP2013007215A0 (en) 2013-10-31
EP2694510B1 (fr) 2015-10-14
AU2012238589A1 (en) 2013-11-07
DK2694510T3 (en) 2016-01-18

Similar Documents

Publication Publication Date Title
MA35016B1 (fr) Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt
MX339873B (es) Inhibidores de serina/treonina cinasa.
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
CO6831982A2 (es) Pirazolo[4,3-d]pirimidinas útiles como inhibidores de cinasas
MX340756B (es) Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
MD20140047A2 (ro) Inhibitori ai protein kinazei
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MX359032B (es) Inhibidores de pirrolopirazina cinasa.
CR20130470A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [2,3-d]PIRIMIDINA TROMPOMIOSINA
AU2012214029A8 (en) Rorgammat inhibitors
AU2012250958A8 (en) Amino-pyridine-containing Spleen Tyrosine Kinase (Syk) inhibitors
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
IN2014MN02082A (fr)
IN2014MN01521A (fr)
MX2013015308A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
MX349548B (es) Compuestos de tienopirimidina.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
WO2012104823A3 (fr) Composés pyridopyrimidinones dans le traitement de maladies neurodégénératives
IN2014DN06964A (fr)
WO2013178322A8 (fr) Dérivés de spiro-tetrahydro-benzothiophène utilisés pour traiter les maladies neurodégénératives
IN2014MN00850A (fr)
GB201107985D0 (en) Process